StockDenmarkNasdaqGS

ASND

Ascendis Pharma A/S

Healthcare · Biotechnology

260.81USD

-9.2800 (-3.44%)

Description Historical Financials Relative Value Research News Discussion OptionsPrice Chart ↗Fundamental Chart ↗

Fiscal Year End12/2025

Last Quarter End03/2026 Q1

Current/T12M(EUR)

Issue Data

Last PxUSD / 260.81

P/E34.5

Dvd Ind Yld—

P/B35.06

P/S19.8

Curr EV/T12M EBITDA—

Mkt Cap (USD)17.1B

Curr EV (USD)—

Per Share Data

EPS T12M7.38

DPS—

Bk Val Per Sh25.40

Rev/Sh13.42

Cash/Sh12.37

Curr Shares Out65.6M

FCF/Sh0.81

Cash Flow Analysis

P/CF282.8

Curr P/FCF329.0

CF/NI0.1

Dvd P/O0.0%

Cash Gen/Cash Reqd—

Csh Dvd Cov—

CFO/Sales7.0%

Eff Interest Rate16.1%

Growth Potential

Dil EPS 1Y Gr42.4%

Cap 1Y Gr-5.6%

BPS 1Y Gr-47.0%

R&D To Sales31.9%

Retention Rate100.0%

Rev 1Y Gr98.0%

FCF 1Y Gr114.8%

Assets 1Y Gr10.4%

Profitability

EBITDA0.0B

EBIT-0.0B

Operating Margin-1.2%

Pretax Margin-19.3%

Net Margin57.3%

ROA32.4%

ROE332.7%

ROC—

Asset Turnover0.56

Structure

Current Ratio1.00

Quick Ratio2.23

Debt/Assets44.8%

Debt/Com Eq183.8%

Net Debt/EBITDA48.55

Tot Debt/Capital64.8%

Gross Margin89.0%

EBIT/Int Exp-0.1

Returns and turnover use the AVERAGE balance over the year, not the closing snapshot. Growth rates compare the two most recent fiscal years. This company reports in a different currency from the one its shares trade in, so any ratio dividing a market value by a statement figure crosses that boundary un-converted.

Reading financial statements from SEC filings…

A first visit to a security takes a few seconds.